NASDAQ:KLRA Kailera Therapeutics Q1 2026 Earnings Report $10.39 -0.64 (-5.80%) As of 10/2/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Kailera Therapeutics EPS ResultsActual EPS-$3,650.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AKailera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKailera Therapeutics Announcement DetailsQuarterQ1 2026Date5/26/2026TimeAfter Market ClosesConference Call DateTuesday, May 26, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Kailera Therapeutics Earnings HeadlinesKailera Therapeutics (NASDAQ:KLRA) Stock Price Down 5.6% - Should You Sell?1 hour ago | americanbankingnews.comKailera Therapeutics Inc Presents New Phase 1 Data For Ribupatide Injection At EASD 2026 Annual MeetingOctober 1 at 5:39 PM | marketscreener.comMYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 3 at 1:00 AM | Profits Run (Ad)Kailera Therapeutics Announces Phase 1 Ribupatide Data Showing Flexible Injection Sites and Additional Hengrui Pharma Clinical Presentations at EASD 2026October 1 at 6:51 AM | quiverquant.comQKailera Therapeutics Presents New Clinical Data at EASD 2026 Annual MeetingOctober 1 at 6:45 AM | globenewswire.comKailera Therapeutics, Inc. Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program Of Ribupatide InjectionSeptember 30 at 3:30 PM | marketscreener.comMSee More Kailera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kailera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kailera Therapeutics and other key companies, straight to your email. Email Address About Kailera TherapeuticsKailera Therapeutics (NASDAQ:KLRA) is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions. Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector. Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals. Publicly available information about its leadership team and broader commercial operations is limited.View Kailera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
